Standard Biotools Inc (OQ:LAB)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 2 Tower Place, Suite 2000
SOUTH SAN FRANCISCO CA 94080
Tel: N/A
Website: https://www.standardbio.com
IR: See website
<
Key People
Tom Carey
Chairman of the Board
Michael Egholm
President, Chief Executive Officer, Director
Jeffrey G. Black
Chief Financial Officer, Senior Vice President
Hanjoon Alex Kim
Chief Operating Officer
Shane Bowen
Chief Technology Officer
Jeremy Davis
Chief Commercial Officer
Adam Taich
Chief Strategy Officer
   
Business Overview
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
Financial Overview
For the fiscal year ended 31 December 2023, Standard Biotools Inc revenues increased 9% to $106.3M. Net loss decreased 61% to $74.7M. Revenues reflect Proteomics segment increase of 22% to $63.9M, China segment increase of 40% to $15.8M, United States segment increase of 8% to $44.1M. Lower net loss reflects Loss on forward sale of Series B Preferr decrease from $60.1M (expense) to $0K, Loss on bridge loans decrease from $13.7M (expense) to $0K.
Employees: 534 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,271M as of Dec 31, 2023
Annual revenue (TTM): $106.34M as of Dec 31, 2023
EBITDA (TTM): -$47.86M as of Dec 31, 2023
Net annual income (TTM): -$74.66M as of Dec 31, 2023
Free cash flow (TTM): -$46.12M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 290,117,930 as of Feb 21, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.